The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Machine learning prediction of prognosis in lung cancer with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).
 
Yukihiro Toi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; TAIHO PHARMACEUTICAL
 
Daichi Fujimoto
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson/Janssen; Kyowa Kirin; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma
Research Funding - AstraZeneca Japan; Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Hidetoshi Hayashi
Honoraria - 3H Clinical Trial; Amgen; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Janssen; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure K.K.
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Ascent Development Services (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol Myers Squibb Company (Inst); Chugai Pharma (Inst); CMIC CO., Ltd. (Inst); Daiichi Sankyo Co., Ltd. (Inst); Eisai (Inst); Eisai (Inst); EPS Holdings (Inst); EPS Holdings (Inst); GlaxoSmithKline K.K. (Inst); IQVIA Services JAPAN K.K (Inst); Janssen (Inst); Kobayashi Pharmaceutical (Inst); Kyowa Kirin Co., Ltd (Inst); Labcorp Drug Development (Inst); Lilly Japan (Inst); Medpace Japan KK (Inst); Merck (Inst); MSD K.K. (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); PRA Health Sciences Inc. (Inst); Sanofi (Inst); Shionogi (Inst); SRL Medisearch Inc. (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Kenta Murotani
Consulting or Advisory Role - Otsuka
Speakers' Bureau - AstraZeneca; Chugai Pharma; MSD; Nippon Shinyaku; Pfizer; Taiho Pharmaceutical
 
Toshihide Yokoyama
No Relationships to Disclose
 
Seigo Katakura
Honoraria - AstraZeneca; Bristol Myers Squibb; Chugai Pharma; MSD K.K.; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca
 
Teppei Yamaguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Lilly; Merck; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo
 
Kaoru Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Kyowa Kirin Co., Ltd.; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Satoru Miura
Consulting or Advisory Role - AstraZeneca; Chugai Pharma
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Motohiro Tamiya
Honoraria - Amgen; Asahi Kasei; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Kirin International; Lilly Japan; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Pfizer
Research Funding - Boehringer Ingelheim; MSD; Ono Pharmaceutical
 
Motoko Tachihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; takeda
Research Funding - AstraZeneca (Inst)
 
Takehito Shukuya
Honoraria - AMGEN; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD; Nippon kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Chugai Pharma; MSD; Novartis
 
Yuko Tsuchiya-Kawano
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Yuki Sato
Honoraria - AstraZeneca; Bristol-Myers Squibb Co Ltd; Chugai Pharma; Daiichi Sankyo/Arqule; Kyowa Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Satoshi Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca
Research Funding - AstraZeneca; Chugai Pharma (Inst)
 
Shinya Sakata
Honoraria - AstraZeneca; Chugai Pharma; Takeda
 
Takeshi Masuda
No Relationships to Disclose
 
Shinnosuke Takemoto
No Relationships to Disclose
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Mebix (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)